Genmab — December 2020
-
FierceBiotech -
ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment https://www.fiercebiotech.com/biotech/ash-j-j-links-subcut-bcma-bispecific-to-73-response-rate-plots-aggressive-investment -
"The responses, which J&J said deepened over time, were seen in patients failed by multiple other therapies. Across the study, patients had received a median of six prior lines of treatment. Almost 40% of the participants were refractory to two or more immunomodulatory agents, two or more proteasome inhibitors and an anti-CD38 therapy. Such patients have few treatment options today".
-
-
5-6%
-
Det tager tid før man kan konstatere om de vil æde af daras markedsandele
-
Genmab har hexa-cd38 i baghånden, som måske er endnu bedre end T&T, også med 20% royalty
-
Er hexacd38 en del af den nuværende partneraftale med JnJ, med samme royalty og en
forlængelse af patentet? -
-
20% royalty til 2031, derefter 13-20%
-
Tak GB. Er det normalt der ikke fremgår end date på perioden med 13-20 %?
-
Med hexa-cd38 succes vil det fjerne en stor del af den potentielle downside på igangværende voldgift med JnJ?
-
Ja
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind